1417. Evaluating the Dissonance Between C(max) and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as...

por Onufrak, Nikolas J, Bhavnani, Sujata M, Pogue, Jason M, Rubino, Christopher M
Publicado 2018

Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients

por Schmitz, Michael L., Rubino, Christopher M., Onufrak, Nikolas J., Martinez, Diana Valencia, Licursi, Diane, Karpf, Angela, Cetnarowski, Wes
Publicado 2020

2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Sur...

por Bhavnani, Sujata M, Onufrak, Nikolas J, Hammel, Jeffrey P, Andes, David R, Bradley, John S, Flamm, Robert K, Ambrose, Paul G, Jones, Ronald N
Publicado 2018

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

por Rubino, Christopher M., Onufrak, Nikolas J., van Ingen, Jakko, Griffith, David E., Bhavnani, Sujata M., Yuen, Dayton W., Mange, Kevin C., Winthrop, Kevin L.
Publicado 2021

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease

por Rubino, Christopher M., Onufrak, Nikolas J., van Ingen, Jakko, Griffith, David E., Bhavnani, Sujata M., Yuen, Dayton W., Mange, Kevin C., Winthrop, Kevin L.
Publicado 2021

1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model

por VanScoy, Brian D, Onufrak, Nikolas J, Conde, Haley, Caranco, Ana I, Bhavnani, Sujata M, Cotroneo, Nicole, Critchley, Ian A, Parr, Thomas R, Ambrose, Paul G
Publicado 2019